COMPANY PROFILE

Pathway Genomics

Explore full profile

Global clinical lab offering genetic tests for cancer risk, drug responses, and many other conditions

San Diego, United StatesFounded 2008Biotech & Life Sciences

Valuation $100–250M Last recorded · 2016

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

At a glance

Status: Operational
Founded: 2008
Headquarters: San Diego, United States
Employees: 34
Open positions: None listed
Dealroom signal: 17.8/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Testing, Risk Management, Biotechnology, Oncology, DNA, Genetics and genomics, Core AI
Technology: Artificial Intelligence, Deep Tech, Machine Learning
Business model: Manufacturing
Client focus: b2b
Links: LinkedIn X

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
OtherOther financing	Nov 2021	$0	—	Undisclosed	—
SERIES E✓Equity / VC	Jan 2016	$40M	$160M	IBM	—

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Pathway Genomics website traffic

Latest recorded traffic for Pathway Genomics is 15K monthly website visits, up 500% over the last three months. Pathway Genomics's team grew 0% over the past year.

Latest monthly visits15K 3-month web change+500% 1-year team growth0%

Monthly website visitsJan 2017–Oct 2022

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
IMInSilico MedicineDevelops an AI platform for drug development to treat cancer and age-related diseases	Cambridge, United States	Operational	294	$532M	$3B
ETEmedgene technologiesEmedgene uses AI to automatically interpret genetic tests, so that health organizations can scale personalized care to wider populations	Palo Alto, United States	Acquired
FGFabric GenomicsGlobal healthcare platform for genomic data analysis - Formerly Omicia	San Francisco, United States	Acquired
PTPear TherapeuticsPear discovers, develops, and commercializes Prescription Digital Therapeutics to treat diseases with high unmet need	Boston, United States	Operational
CBCancer Genetics (Vyant Bio)Cancer Genetics is laboratory that develops and commercializes proprietary genomic tests and services to empower cancer treatment	Rutherford, United States	Operational
GHGuardant HealthImproving patient health through technology breakthroughs in oncology.	Palo Alto, United States	Operational
2323andMeHelping people access, understand, and benefit from the human genome	Sunnyvale, United States	Acquired
JUJunglaWe increasingly look to our genomes for answers Jungla is committed to ensuring we find them	South San Francisco, United States	Operational